Skip to content

Evaluation of pre- and post-antibiotic chemoprophylaxis on the risk of infection after abdominoplasty: a randomized controlled trial study

Evaluation of pre- and post-antibiotic chemoprophylaxis on the risk of infection after abdominoplasty: a randomized controlled trial study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20251121068065N2
Enrollment
80
Registered
2026-05-21
Start date
2026-06-05
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: ?Surgical site infection (SSI). Condition 2: Antibiotic-related side effects. Infection following a procedure

Interventions

Intervention 1: Intervention Group 1 (Group A): Receiving a single dose of cefazolin 2 g intravenously, one hour before surgery. Intervention 2: Intervention Group 2 (Group B): Receiving a single dose

Sponsors

Dr. Mohamed Amin Ghobadifar
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients who are elective candidates for abdominoplasty. Age between 18 and 65 years. American society of anesthesiologists classification (ASA) class I or II. Willingness to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: History of repeat abdominoplasty. History of allergy or hypersensitivity to cephalosporins (e.g., cephalexin) or penicillins. Need for preoperative antibiotic administration due to conditions such as underlying infection or valvular heart disease. Immunodeficiency caused by diseases such as AIDS and malignancies, or by medications such as corticosteroids and immunosuppressive drugs. History of steroid use. Presence of chronic kidney disease, peripheral vascular disease, uncontrolled hypertension, or pulmonary disease. History of radiotherapy. Chronic skin disease. Recent surgery. American society of anesthesiologists classification (ASA) class III or higher. Refusal to participate in the study.

Design outcomes

Primary

MeasureTime frame
The incidence of surgical site infection (SSI). Timepoint: All patients are followed up for 30 days after surgery to assess infections. This includes weekly in-person evaluations by the surgeon and phone calls every 3 days to document the patients’ status. Method of measurement: 1.Observation of infection with purulent discharge from the wound. 2.If there is discharge, a microbiological culture of fluids or tissue obtained from the wound incision is positive. 3.Pain, tenderness, swelling, redness, and/or warmth occurs in the wound area. 4.The wound infection is diagnosed based on the surgeon’s clinical judgment.;Side effects of antibiotics (such as diarrhea, nausea, skin rashes). Timepoint: All patients are followed up for 30 days after surgery to assess antibiotic-related side effects. This includes weekly in-person evaluations by the surgeon and phone calls every 3 days to document the patients’ status. Method of measurement: Evaluations will perform by a physician.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehrdad Mirzaee Rozbahani

Lorestan University of Medical Science

dr.mirzae@gmail.com+98 912 502 5200

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026